Combination chemo-immunotherapy does not improve survival compared with
chemotherapy alone for advanced malignant melanoma × Close The Infona portal uses …

Recent data have demonstrated improved survival with targeted and immune therapies in
patients with advanced melanoma, leading to much excitement amongst the oncology …

Malignant melanoma (MM) is a neoplasm of the cells that develops from melanocytes.
Although belived to be uncommon and despite campaigns that advocate safe sun exposure …

Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence
Page 1 CURRENT OPINION Single agent vs combination immunotherapy in advanced …

The dual combination of the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib as a
treatment for patients with metastatic or unresectable melanoma harboring a BRAF V600E …

Immunotherapy has dramatically improved the prognosis for patients with melanoma and
has become the cornerstone of treatment for those with advanced disease. The role of …

The introduction of immunotherapy‐based strategies has significantly improved the
prognosis for melanoma patients. Nevertheless, some patients still have dismal outcomes …

In the last years, the treatment of metastatic melanoma has been experiencing a continuous
revolution. Immunotherapy represents a treatment strategy that targets different mechanisms …

Historically, the median overall survival for patients with stage IV melanoma was less than 1
year and the 5-year survival rate was∼ 10%. Recent advances in therapy have raised 5 …

e21017 Background: In the past 5 years, the treatment of metastatic melanoma has rapidly
evolved with the commercial approval of immune and targeted therapies. While each …